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Vaccines against SARS-CoV-2 infection have 
recently become available and have been used in 
various countries around the world since end of 
2020. Although overall good tolerability has been 
reported, several anaphylactic reactions have been 
described following vaccination. Vaccination against 
COVID-19 is an essential global intervention to 
control the current pandemic. Vaccines often result 
in adverse events which are majorly a consequence 
of the vaccine stimulating a protective immune 
response, and not allergic reactions. Anaphylaxis as 
an adverse event following immunization is 
uncommon, occurring at a rate of less than 1 per 
million doses for most vaccines.1 Ideally, patients 
with a history of severe allergy should not be 
vaccinated, but given the high prevalence of allergic 
diseases, this may result in several people being 
necessarily deprived of vaccination, making herd 
immunity more difficult to achieve. The current 
recommendation of the European regulatory 
authority states that patients with known allergy to 
the ingredients contained in the vaccine should not 
be vaccinated. It has furthermore been noted that a 
very small number of severe allergic reactions have 
occurred since vaccination was started. Vaccinations 
should generally be administered under medical 
supervision which allows for emergency treatment. 
People  who  develop  a  severe allergic reaction after  
 
the first vaccination should not be administered the 
second dose of the vaccine. 
 
Allergic reactions to vaccines are very rare and are 
usually induced by sensitization of the vaccinated 
person to ingredients of the vaccine. Besides the 
specific viral mRNA vaccines contain a number of 
additives which may theoretically precipitate an 
allergic reaction. Allergic or allergy-like reactions 
can possibly be precipitated by polyethylene glycol 
(PEG) also known as macrogol which is present as an 
additive in new vaccines for stabilization of 
nanoparticles and may also be present in many other 
oral or intravenous preparations.2 PEG is known to 
give rise to harmless, delayed-onset contact allergic 
reactions as well as isolated cases of immediate-type 
reactions including anaphylaxis.3,4 Another possible 
mechanism currently being discussed is 
complement-mediated mast cell activation by PEG 
specific IgG and/or IgM antibodies also known as 
complement-activation-related-pseudoallergy.5 
 
Many healthy individuals are known to have specific 
antibodies against PEG. Allergic reactions may be 
due to immunologically mediated hypersensitivity 
reactions of varying severity to foreign substances, 
only some of which are life-threatening. Anaphylaxis 
is   the  maximum   variant   of   an   immediate-type  
 
 














The SARS-CoV-2 coronavirus responsible for the COVID-19 pandemic has led to a major health crisis and high mortality rates. Progression 
to a severe and potentially fatal form of COVID-19 is associated not only with massive viral replication, but also with an inappropriate 
inflammatory response against the SARS-CoV-2 virus. Therefore, drug strategies may target not only the viral infection itself, but also 
inappropriate immunoinflammatory responses. Numerous wide-ranging medications have been attempted to improve the prognosis and 
outcome of COVID-19, especially among hospitalized patients due to an acute respiratory distress syndrome. Vaccination against COVID-
19 is an essential global intervention to control the current pandemic situation. Vaccines often cause adverse events; however, the vast 
majority of adverse events following immunization are due to the protective immune response induced by the vaccine, and not due to an 
allergic reaction. It is important to know that how can SARS-CoV-2 vaccines be administered with minimal risk of allergic reactions. In 
fact, currently available mRNA vaccines may usually be administered readily even to patients with allergies. The following review describes 
the risk of severe anaphylaxis and provides practical tips for safe vaccination. 
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allergic reaction which manifests in various organ 
systems and may be potentially life threatening. This 
must be distinguished from non-IgE-mediated 
immediate reactions. Polysorbate 80 is also one of 
the ingredient of some of the current non-mRNA-
based COVID vaccines and this molecule has also 
been reported to cause anaphylaxis-like reactions in 
animal studies6 but there are only a few cases of 
adverse events in human subjects.7,8 
 
RECOMMENDATIONS FOR PRACTICE 
Possible adverse reactions after vaccination include 
anaphylaxis, which occurs very rarely, as well as 
marked local reactions, worsening of symptoms of 
an existing allergic disease, which may very rarely 
evolve into a life-threatening condition only after 
several days. The current focus is on the possibility 
of acute anaphylaxis. A previous severe allergic 
reaction to any component of the SARS-CoV-2 
vaccine is an absolute contraindication to 
vaccination. Other risk constellations from an 
allergological point of view include patients with a 
history of anaphylaxis to an indeterminate triggering 
agent, to previous vaccinations or medication with 
pre-existent mastocytosis. However, anaphylaxis 
after insect bites or foodstuffs does not constitute a 
contraindication to COVID-19 vaccination with 
mRNA vaccines, according to current state of 
knowledge. As a precautionary measure, patients 
with a history of anaphylactic reaction to foodstuffs 
were excluded from certain vaccinations, since 
residual components of food allergens may trigger 
allergic reactions during vaccinations in isolated 
cases. Patients with food allergy are not expected to 
be at higher risk of allergy to COVID-19 vaccination. 
Detailed medical history should be evaluated for 
potential risk to the patient. If the constellation is 
unclear, allergy testing should be undertaken in a 
timely manner before vaccination to determine the 
triggering substance.  
 
Patients may be vaccinated if they are found to have 
anaphylaxis to defined drugs or additives not 
included in the vaccine. This procedure requires 
appropriate information and education of both 
immunization teams as well as individuals willing to 
be vaccinated. It is likely that absolute 
contraindications to SARS-CoV-2 vaccination are 
rare in patients with underlying allergies. However, 
the frequency of severe allergic reactions to mRNA-
based vaccines, their underlying mechanism and 
individuals at particular risk must be observed very 
carefully over time. Notification regarding the 
implementation of SARS-CoV-2 vaccination should 
provide guidance regarding the need for 
allergological evaluation in case a history of certain 
risk factors is present. This facilitates an initial 
discussion including medical history at the 
vaccination center. Anti-allergic premedication 
should be considered in addition to the specified 
provision of emergency medical care in the event 
that allergological tests yield equivocal results. This 
may be considered for instance in patients with a 
history of perioperative or contrast-induced 
anaphylaxis or of anaphylaxis of indeterminate 
origin. Antihistamines and an oral glucocorticoid 
should be administered prophylactically. 
Premedication may also be considered in subjects 
who are evidently very afraid of possible vaccine 
reactions following rational explanation in an 
attempt to prevent nocebo reactions. The injection 
may be given after obtaining a brief history and 
exclusion of contraindications which should be 
checked from the labelling document of the vaccine 
provided by the manufacturer. A 30-minute post-
injection follow-up is recommended in people with 
a history of anaphylaxis due to possible side effects. 
The vaccination team must be informed about the 
possibility of anaphylaxis and trained in its acute 
treatment. Necessary medication and supplies must 




The worldwide incidence of allergies has increased 
over the past several decades. Drug-induced 
anaphylactic reactions are a rare but real problem in 
clinical medicine. A blanket exclusion of all patients 
with allergy from SARS-CoV-2 vaccination is 
irrational and should be avoided. Adequate 
allergological testing should be performed in the 
presence of an appropriate history in order to 
determine the true risk of anaphylaxis after SARS-
CoV-2 vaccination. This is best done before a 
vaccination appointment. All individuals 
administering vaccination should be explicitly 
trained in the identification and management of 
anaphylactic reactions and must have access to 
necessary equipment, including epinephrine auto-
injectors. Pharmacological premedication with 
histamine H1 and H2 antagonists plus 
glucocorticoids prior to vaccination may be 
considered in equivocal cases and in patients with 
hypochondriac anxiety. It is important to report any 
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severe allergic reaction related to vaccination. We 
have analyzed the risk of anaphylaxis due to COVID-
19 vaccination from an allergological perspective and 
also highlighted the basic principles for prevention 
and therapy of anaphylactic reactions and proposed 
measures for practical management of vaccination 
against SARS-CoV-2. There is a further need to 
evaluate the risk of anaphylaxis for the recently 
approved COVID-19 mRNA vaccines by analyzing 
the data available in the current literature. 
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